Hepion Pharmaceuticals, Inc. (HEPA) 10-Year Financial Performance & Capital Metrics

HEPA • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Show more

Revenue $0
EBITDA -$19M +60.1%
Net Income -$13M +73.0%
EPS (Diluted) -107.35 +82.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -487.03% -184.4%
ROIC -2302.24%
Debt/Equity -
Interest Coverage -15.51 +99.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Shares diluted 54.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM59.62%

EPS CAGR

10Y-

5Y-

3Y-

TTM93.89%

ROCE

10Y Avg-165.06%

5Y Avg-132.22%

3Y Avg-184.5%

Latest-343.2%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Jun 2016	Jun 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	21.52K	0	21.94K	18.79K	26.74K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-21.52K	0	-21.94K	-18.79K	-26.74K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.32%	1%	-	0.14%	-0.42%	1%	-	-	-	-
Operating Expenses+	20.81M	21.02M	21.02M	14.59M	7.77M	20.15M	30.4M	45.49M	48.45M	19.35M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.79M	7.37M	6.69M	7M	4.59M	8.15M	10.01M	10.35M	9.62M	7.5M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	15.02M	13.65M	14.33M	7.59M	3.18M	12M	20.4M	33.27M	35.64M	11.85M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-108.94K	0	0	0	1.87M	3.19M	0
Operating Income+	-20.81M	-21.02M	-21.04M	-14.59M	-7.77M	-20.15M	-30.4M	-45.49M	-48.45M	-19.35M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.49%	-0.01%	-0%	0.31%	0.47%	-1.59%	-0.51%	-0.5%	-0.07%	0.6%
EBITDA+	-20.78M	-21M	-21.02M	-14.58M	-7.74M	-20.11M	-30.32M	-45.41M	-48.38M	-19.32M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.49%	-0.01%	-0%	0.31%	0.47%	-1.6%	-0.51%	-0.5%	-0.07%	0.6%
D&A (Non-Cash Add-back)	21.52K	27.99K	21.94K	18.79K	26.74K	34.52K	86.07K	77.46K	67.13K	30.76K
EBIT	-20.59M	-21.02M	-18.92M	-14.59M	-7.77M	-20.15M	-32.71M	-45.07M	-49.33M	-14.91M
Net Interest Income+	0	0	0	0	-555K	-31.23K	-8.86K	-10.16K	-9.46K	-1.25M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	339.16K	555K	31.23K	8.86K	10.16K	9.46K	1.25M
Other Income/Expense	3.81M	4.22M	2.13M	4.61M	-175.94K	-177.28K	-2.32M	404.83K	-887.11K	3.18M
Pretax Income+	-17M	-16.8M	-18.92M	-9.99M	-7.95M	-20.32M	-32.72M	-45.08M	-49.34M	-16.16M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	-1.91M	-3.9M	-536K	-908.68K	30.58K	0	-2.88M	-409.02K	-2.97M
Effective Tax Rate %	1%	0.89%	0.79%	0.95%	0.89%	1%	1%	0.94%	0.99%	0.82%
Net Income+	-17M	-14.89M	-15.02M	-9.45M	-7.04M	-20.35M	-32.72M	-42.2M	-48.93M	-13.19M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.18%	0.12%	-0.01%	0.37%	0.26%	-1.89%	-0.61%	-0.29%	-0.16%	0.73%
Net Income (Continuing)	-17M	-14.89M	-15.02M	-9.45M	-7.04M	-20.35M	-32.72M	-42.2M	-48.93M	-13.19M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-352800.00	-3373.93	-106400.00	-97353.00	-6108.07	-2103.70	-465.52	-594.75	-616.07	-107.35
EPS Growth %	0.38%	0.99%	-30.54%	0.09%	0.94%	0.66%	0.78%	-0.28%	-0.04%	0.83%
EPS (Basic)	-352800.00	-2855.94	-106400.00	-97353.00	-6108.07	-2103.70	-465.52	-594.75	-616.07	-107.35
Diluted Shares Outstanding	48	5.21K	138	184	2.04K	9.68K	70.29K	76.23K	79.42K	122.89K
Basic Shares Outstanding	48	5.2K	138	184	2.04K	9.68K	70.29K	76.23K	79.42K	122.89K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.89M	13.19M	6.06M	2.97M	14.39M	42.63M	97.45M	56.5M	17.49M	1.61M
Cash & Short-Term Investments	7.4M	12.98M	5.95M	2.83M	13.92M	40.73M	91.35M	51.19M	14.79M	406.41K
Cash Only	7.4M	12.98M	5.95M	2.83M	13.92M	40.73M	91.35M	51.19M	14.79M	406.41K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	5.21M	5.19M	5.19M	5.22M	6.22M	6.01M	6.1M	3.75M	606.56K	0
Property, Plant & Equipment	80.85K	67.56K	56.59K	32.43K	855.08K	664.93K	456.46K	3.32M	242.37K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	1.87M	1.87M	1.87M	1.87M	1.87M	1.87M	1.87M	0	0	0
Intangible Assets	3.19M	3.19M	0	3.19M	3.19M	3.19M	3.19M	3.19M	0	0
Long-Term Investments	0	0	0	0	0	-731.3K	0	0	0	0
Other Non-Current Assets	69.95K	63.18K	3.26M	127.79K	306.88K	285.1K	582.85K	-2.76M	364.19K	0
Total Assets+	13.11M	18.38M	11.25M	8.19M	20.61M	48.65M	103.55M	60.24M	18.09M	1.61M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	1.44%	0.4%	-0.39%	-0.27%	1.52%	1.36%	1.13%	-0.42%	-0.7%	-0.91%
Total Current Liabilities+	5.08M	2.94M	2.6M	2.85M	1.61M	4.66M	8.21M	7.89M	5.29M	3.14M
Accounts Payable	4.25M	1.63M	1.56M	748.43K	491.56K	3.72M	2.45M	2.67M	2.35M	220.2K
Days Payables Outstanding	72.11K	-	25.9K	14.54K	6.71K	-	-	-	-	-
Short-Term Debt	0	0	0	1.44M	0	0	0	0	0	2.9M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	2.99M	2.27M	386K	0
Current Ratio	1.55x	4.48x	2.33x	1.04x	8.94x	9.15x	11.88x	7.16x	3.31x	0.51x
Quick Ratio	1.55x	4.48x	2.33x	1.04x	8.94x	9.15x	11.88x	7.16x	3.31x	0.51x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.71M	6.38M	4.95M	3.36M	3.39M	3.46M	2.35M	2.5M	5.52M	333.19K
Long-Term Debt	0	0	0	0	0	176.59K	0	0	0	0
Capital Lease Obligations	0	0	0	0	540.75K	295.75K	50.34K	0	93.1K	0
Deferred Tax Liabilities	1.27M	1.27M	896.7K	360.7K	409.02K	409.02K	0	409.02K	0	0
Other Non-Current Liabilities	5.44M	5.11M	4.05M	3M	2.44M	2.58M	2.3M	2.09M	5.43M	333.19K
Total Liabilities	11.79M	9.33M	7.55M	6.21M	4.99M	8.12M	10.56M	10.39M	10.81M	3.48M
Total Debt+	10.41K	0	0	1.44M	807.45K	752.17K	316.99K	53.61K	209.02K	2.9M
Net Debt	-7.39M	-12.98M	-5.95M	-1.39M	-13.12M	-39.97M	-91.03M	-51.14M	-14.58M	2.49M
Debt / Equity	0.01x	-	-	0.73x	0.05x	0.02x	0.00x	0.00x	0.03x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-43.03x	-14.00x	-645.11x	-3431.91x	-4475.47x	-5118.64x	-15.51x
Total Equity+	1.32M	9.06M	3.7M	1.98M	15.62M	40.52M	93M	49.86M	7.28M	-1.86M
Equity Growth %	-0.62%	5.87%	-0.59%	-0.47%	6.91%	1.59%	1.3%	-0.46%	-0.85%	-1.26%
Book Value per Share	27266.66	1739.22	26783.65	10741.04	7644.00	4187.29	1323.00	654.03	91.68	-15.16
Total Shareholders' Equity	1.32M	9.06M	3.7M	1.98M	15.62M	40.52M	93M	49.86M	7.28M	-1.86M
Common Stock	3.22K	7.57K	7.83K	25	375	3.2K	7.62K	381	482	14
Retained Earnings	-44.61M	-59.5M	-67.01M	-76.46M	-83.75M	-104.11M	-133.5M	-175.7M	-224.63M	-237.82M
Treasury Stock	0	0	6.85K	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	-90.17K	-78.78K	8.35K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.56M	-19.17M	-8.21M	-15.65M	-7.57M	-16.17M	-31.22M	-34.96M	-40.89M	-18.22M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.71%	-0.16%	0.57%	-0.91%	0.52%	-1.14%	-0.93%	-0.12%	-0.17%	0.55%
Net Income	-17M	-14.89M	-15.02M	-9.45M	-7.04M	-20.35M	-32.72M	-42.2M	-48.93M	-13.19M
Depreciation & Amortization	21.52K	27.99K	21.94K	18.79K	26.74K	34.52K	86.07K	77.46K	67.13K	30.76K
Stock-Based Compensation	901.87K	1.7M	1.57K	234.51K	66.18K	2.38M	4.67M	2.55M	1.34M	791.64K
Deferred Taxes	0	-4.22M	-372.92K	-536K	48.32K	0	0	0	-409.02K	0
Other Non-Cash Items	-3.81M	-4.17M	7.34M	-4.94M	157.28K	146.05K	2.31M	1.46M	4.07M	-3.16M
Working Capital Changes	3.33M	-1.84M	-19.21K	-970.48K	-826.23K	1.63M	-5.57M	3.15M	2.97M	-2.68M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	-111.21K	-897.7K	-317.05K	0	-1.07M	0	0	0
Cash from Investing+	-502.21K	-14.71K	-2	900	-51.47K	-85.79K	-130.41K	-14.07K	-14.3K	-600K
Capital Expenditures	-6.6K	-14.71K	-2	0	-51.47K	-87.98K	-130.41K	-16.34K	-14.3K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	1	0	2.19K	0	2.27K	0	-600K
Cash from Financing+	19.9M	24.77M	1.18M	12.52M	18.71M	43.05M	81.98M	-5.14M	4.49M	4.35M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	19.9M	116.28K	11.9M	-857.4K	2.09M	12K	0	-2M	4.49M	1.85M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.56M	-19.19M	-8.21M	-15.65M	-7.62M	-16.25M	-31.35M	-34.98M	-40.9M	-18.22M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.7%	-0.16%	0.57%	-0.91%	0.51%	-1.13%	-0.93%	-0.12%	-0.17%	0.55%
FCF per Share	-342736.18	-3684.11	-59374.94	-85088.71	-3728.11	-1679.57	-446.07	-458.85	-515.05	-148.23
FCF Conversion (FCF/Net Income)	0.97x	1.29x	0.55x	1.66x	1.07x	0.79x	0.95x	0.83x	0.84x	1.38x
Interest Paid	0	0	0	0	0	0	0	941	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-714.73%	-287.04%	-235.44%	-332.83%	-80.01%	-72.52%	-49.02%	-59.08%	-171.26%	-487.03%
Return on Invested Capital (ROIC)	-	-	-	-1878.68%	-377.95%	-991.8%	-1817.84%	-9983.03%	-	-2302.24%
Debt / Equity	0.01x	-	-	0.73x	0.05x	0.02x	0.00x	0.00x	0.03x	-
Interest Coverage	-	-	-	-43.03x	-14.00x	-645.11x	-3431.91x	-4475.47x	-5118.64x	-15.51x
FCF Conversion	0.97x	1.29x	0.55x	1.66x	1.07x	0.79x	0.95x	0.83x	0.84x	1.38x

Frequently Asked Questions

Growth & Financials

Hepion Pharmaceuticals, Inc. (HEPA) grew revenue by 0.0% over the past year. Growth has been modest.

Hepion Pharmaceuticals, Inc. (HEPA) reported a net loss of $9.2M for fiscal year 2024.

Dividend & Returns

Hepion Pharmaceuticals, Inc. (HEPA) has a return on equity (ROE) of -487.0%. Negative ROE indicates the company is unprofitable.

Hepion Pharmaceuticals, Inc. (HEPA) had negative free cash flow of $4.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Hepion Pharmaceuticals, Inc. (HEPA) 10-Year Financial Performance & Capital Metrics

HEPA • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $0
EBITDA -$19M +60.1%
Net Income -$13M +73.0%
EPS (Diluted) -107.35 +82.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -487.03% -184.4%
ROIC -2302.24%
Debt/Equity -
Interest Coverage -15.51 +99.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Shares diluted 54.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM59.62%

EPS CAGR

10Y-

5Y-

3Y-

TTM93.89%

ROCE

10Y Avg-165.06%

5Y Avg-132.22%

3Y Avg-184.5%

Latest-343.2%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Jun 2016	Jun 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	21.52K	0	21.94K	18.79K	26.74K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-21.52K	0	-21.94K	-18.79K	-26.74K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.32%	1%	-	0.14%	-0.42%	1%	-	-	-	-
Operating Expenses+	20.81M	21.02M	21.02M	14.59M	7.77M	20.15M	30.4M	45.49M	48.45M	19.35M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.79M	7.37M	6.69M	7M	4.59M	8.15M	10.01M	10.35M	9.62M	7.5M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	15.02M	13.65M	14.33M	7.59M	3.18M	12M	20.4M	33.27M	35.64M	11.85M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-108.94K	0	0	0	1.87M	3.19M	0
Operating Income+	-20.81M	-21.02M	-21.04M	-14.59M	-7.77M	-20.15M	-30.4M	-45.49M	-48.45M	-19.35M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.49%	-0.01%	-0%	0.31%	0.47%	-1.59%	-0.51%	-0.5%	-0.07%	0.6%
EBITDA+	-20.78M	-21M	-21.02M	-14.58M	-7.74M	-20.11M	-30.32M	-45.41M	-48.38M	-19.32M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.49%	-0.01%	-0%	0.31%	0.47%	-1.6%	-0.51%	-0.5%	-0.07%	0.6%
D&A (Non-Cash Add-back)	21.52K	27.99K	21.94K	18.79K	26.74K	34.52K	86.07K	77.46K	67.13K	30.76K
EBIT	-20.59M	-21.02M	-18.92M	-14.59M	-7.77M	-20.15M	-32.71M	-45.07M	-49.33M	-14.91M
Net Interest Income+	0	0	0	0	-555K	-31.23K	-8.86K	-10.16K	-9.46K	-1.25M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	339.16K	555K	31.23K	8.86K	10.16K	9.46K	1.25M
Other Income/Expense	3.81M	4.22M	2.13M	4.61M	-175.94K	-177.28K	-2.32M	404.83K	-887.11K	3.18M
Pretax Income+	-17M	-16.8M	-18.92M	-9.99M	-7.95M	-20.32M	-32.72M	-45.08M	-49.34M	-16.16M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	-1.91M	-3.9M	-536K	-908.68K	30.58K	0	-2.88M	-409.02K	-2.97M
Effective Tax Rate %	1%	0.89%	0.79%	0.95%	0.89%	1%	1%	0.94%	0.99%	0.82%
Net Income+	-17M	-14.89M	-15.02M	-9.45M	-7.04M	-20.35M	-32.72M	-42.2M	-48.93M	-13.19M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.18%	0.12%	-0.01%	0.37%	0.26%	-1.89%	-0.61%	-0.29%	-0.16%	0.73%
Net Income (Continuing)	-17M	-14.89M	-15.02M	-9.45M	-7.04M	-20.35M	-32.72M	-42.2M	-48.93M	-13.19M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-352800.00	-3373.93	-106400.00	-97353.00	-6108.07	-2103.70	-465.52	-594.75	-616.07	-107.35
EPS Growth %	0.38%	0.99%	-30.54%	0.09%	0.94%	0.66%	0.78%	-0.28%	-0.04%	0.83%
EPS (Basic)	-352800.00	-2855.94	-106400.00	-97353.00	-6108.07	-2103.70	-465.52	-594.75	-616.07	-107.35
Diluted Shares Outstanding	48	5.21K	138	184	2.04K	9.68K	70.29K	76.23K	79.42K	122.89K
Basic Shares Outstanding	48	5.2K	138	184	2.04K	9.68K	70.29K	76.23K	79.42K	122.89K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.89M	13.19M	6.06M	2.97M	14.39M	42.63M	97.45M	56.5M	17.49M	1.61M
Cash & Short-Term Investments	7.4M	12.98M	5.95M	2.83M	13.92M	40.73M	91.35M	51.19M	14.79M	406.41K
Cash Only	7.4M	12.98M	5.95M	2.83M	13.92M	40.73M	91.35M	51.19M	14.79M	406.41K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	5.21M	5.19M	5.19M	5.22M	6.22M	6.01M	6.1M	3.75M	606.56K	0
Property, Plant & Equipment	80.85K	67.56K	56.59K	32.43K	855.08K	664.93K	456.46K	3.32M	242.37K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	1.87M	1.87M	1.87M	1.87M	1.87M	1.87M	1.87M	0	0	0
Intangible Assets	3.19M	3.19M	0	3.19M	3.19M	3.19M	3.19M	3.19M	0	0
Long-Term Investments	0	0	0	0	0	-731.3K	0	0	0	0
Other Non-Current Assets	69.95K	63.18K	3.26M	127.79K	306.88K	285.1K	582.85K	-2.76M	364.19K	0
Total Assets+	13.11M	18.38M	11.25M	8.19M	20.61M	48.65M	103.55M	60.24M	18.09M	1.61M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	1.44%	0.4%	-0.39%	-0.27%	1.52%	1.36%	1.13%	-0.42%	-0.7%	-0.91%
Total Current Liabilities+	5.08M	2.94M	2.6M	2.85M	1.61M	4.66M	8.21M	7.89M	5.29M	3.14M
Accounts Payable	4.25M	1.63M	1.56M	748.43K	491.56K	3.72M	2.45M	2.67M	2.35M	220.2K
Days Payables Outstanding	72.11K	-	25.9K	14.54K	6.71K	-	-	-	-	-
Short-Term Debt	0	0	0	1.44M	0	0	0	0	0	2.9M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	2.99M	2.27M	386K	0
Current Ratio	1.55x	4.48x	2.33x	1.04x	8.94x	9.15x	11.88x	7.16x	3.31x	0.51x
Quick Ratio	1.55x	4.48x	2.33x	1.04x	8.94x	9.15x	11.88x	7.16x	3.31x	0.51x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.71M	6.38M	4.95M	3.36M	3.39M	3.46M	2.35M	2.5M	5.52M	333.19K
Long-Term Debt	0	0	0	0	0	176.59K	0	0	0	0
Capital Lease Obligations	0	0	0	0	540.75K	295.75K	50.34K	0	93.1K	0
Deferred Tax Liabilities	1.27M	1.27M	896.7K	360.7K	409.02K	409.02K	0	409.02K	0	0
Other Non-Current Liabilities	5.44M	5.11M	4.05M	3M	2.44M	2.58M	2.3M	2.09M	5.43M	333.19K
Total Liabilities	11.79M	9.33M	7.55M	6.21M	4.99M	8.12M	10.56M	10.39M	10.81M	3.48M
Total Debt+	10.41K	0	0	1.44M	807.45K	752.17K	316.99K	53.61K	209.02K	2.9M
Net Debt	-7.39M	-12.98M	-5.95M	-1.39M	-13.12M	-39.97M	-91.03M	-51.14M	-14.58M	2.49M
Debt / Equity	0.01x	-	-	0.73x	0.05x	0.02x	0.00x	0.00x	0.03x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-43.03x	-14.00x	-645.11x	-3431.91x	-4475.47x	-5118.64x	-15.51x
Total Equity+	1.32M	9.06M	3.7M	1.98M	15.62M	40.52M	93M	49.86M	7.28M	-1.86M
Equity Growth %	-0.62%	5.87%	-0.59%	-0.47%	6.91%	1.59%	1.3%	-0.46%	-0.85%	-1.26%
Book Value per Share	27266.66	1739.22	26783.65	10741.04	7644.00	4187.29	1323.00	654.03	91.68	-15.16
Total Shareholders' Equity	1.32M	9.06M	3.7M	1.98M	15.62M	40.52M	93M	49.86M	7.28M	-1.86M
Common Stock	3.22K	7.57K	7.83K	25	375	3.2K	7.62K	381	482	14
Retained Earnings	-44.61M	-59.5M	-67.01M	-76.46M	-83.75M	-104.11M	-133.5M	-175.7M	-224.63M	-237.82M
Treasury Stock	0	0	6.85K	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	-90.17K	-78.78K	8.35K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.56M	-19.17M	-8.21M	-15.65M	-7.57M	-16.17M	-31.22M	-34.96M	-40.89M	-18.22M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.71%	-0.16%	0.57%	-0.91%	0.52%	-1.14%	-0.93%	-0.12%	-0.17%	0.55%
Net Income	-17M	-14.89M	-15.02M	-9.45M	-7.04M	-20.35M	-32.72M	-42.2M	-48.93M	-13.19M
Depreciation & Amortization	21.52K	27.99K	21.94K	18.79K	26.74K	34.52K	86.07K	77.46K	67.13K	30.76K
Stock-Based Compensation	901.87K	1.7M	1.57K	234.51K	66.18K	2.38M	4.67M	2.55M	1.34M	791.64K
Deferred Taxes	0	-4.22M	-372.92K	-536K	48.32K	0	0	0	-409.02K	0
Other Non-Cash Items	-3.81M	-4.17M	7.34M	-4.94M	157.28K	146.05K	2.31M	1.46M	4.07M	-3.16M
Working Capital Changes	3.33M	-1.84M	-19.21K	-970.48K	-826.23K	1.63M	-5.57M	3.15M	2.97M	-2.68M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	-111.21K	-897.7K	-317.05K	0	-1.07M	0	0	0
Cash from Investing+	-502.21K	-14.71K	-2	900	-51.47K	-85.79K	-130.41K	-14.07K	-14.3K	-600K
Capital Expenditures	-6.6K	-14.71K	-2	0	-51.47K	-87.98K	-130.41K	-16.34K	-14.3K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	1	0	2.19K	0	2.27K	0	-600K
Cash from Financing+	19.9M	24.77M	1.18M	12.52M	18.71M	43.05M	81.98M	-5.14M	4.49M	4.35M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	19.9M	116.28K	11.9M	-857.4K	2.09M	12K	0	-2M	4.49M	1.85M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.56M	-19.19M	-8.21M	-15.65M	-7.62M	-16.25M	-31.35M	-34.98M	-40.9M	-18.22M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.7%	-0.16%	0.57%	-0.91%	0.51%	-1.13%	-0.93%	-0.12%	-0.17%	0.55%
FCF per Share	-342736.18	-3684.11	-59374.94	-85088.71	-3728.11	-1679.57	-446.07	-458.85	-515.05	-148.23
FCF Conversion (FCF/Net Income)	0.97x	1.29x	0.55x	1.66x	1.07x	0.79x	0.95x	0.83x	0.84x	1.38x
Interest Paid	0	0	0	0	0	0	0	941	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-714.73%	-287.04%	-235.44%	-332.83%	-80.01%	-72.52%	-49.02%	-59.08%	-171.26%	-487.03%
Return on Invested Capital (ROIC)	-	-	-	-1878.68%	-377.95%	-991.8%	-1817.84%	-9983.03%	-	-2302.24%
Debt / Equity	0.01x	-	-	0.73x	0.05x	0.02x	0.00x	0.00x	0.03x	-
Interest Coverage	-	-	-	-43.03x	-14.00x	-645.11x	-3431.91x	-4475.47x	-5118.64x	-15.51x
FCF Conversion	0.97x	1.29x	0.55x	1.66x	1.07x	0.79x	0.95x	0.83x	0.84x	1.38x

Frequently Asked Questions

Growth & Financials

Hepion Pharmaceuticals, Inc. (HEPA) grew revenue by 0.0% over the past year. Growth has been modest.

Hepion Pharmaceuticals, Inc. (HEPA) reported a net loss of $9.2M for fiscal year 2024.

Dividend & Returns

Hepion Pharmaceuticals, Inc. (HEPA) has a return on equity (ROE) of -487.0%. Negative ROE indicates the company is unprofitable.

Hepion Pharmaceuticals, Inc. (HEPA) had negative free cash flow of $4.1M in fiscal year 2024, likely due to heavy capital investments.